A primer on Eli Lilly's investigational weight-loss shot, its trial results and the possible timeline for approval and availability.
Recap by typeshit. Full story at Newsweek on MSN.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
Young users describe buying retatrutide, GHK-Cu and BPC-157 online, while doctors say the evidence behind many claims is weak.
Korea's SBS asks whether Wegovy should be covered by national health insurance as reports of vision loss side effects put the drug under scrutiny.
Loading…